Retaspimycin: Preliminary Phase Ib data

Preliminary data from an ongoing, open-label, dose-escalation, U.S. Phase Ib trial (IPI-504-05) in 22 patients showed that IV IPI-504 plus Taxotere docetaxel was well tolerated and produced 1 partial...